A new era in the treatment of multiple sclerosis

View/ Open
File version
Version of Record (VoR)
Author(s)
Broadley, Simon A
Barnett, Michael H
Boggild, Mike
Brew, Bruce J
Butzkueven, Helmut
Heard, Robert
Hodgkinson, Suzanne
Kermode, Allan G
Lechner-Scott, Jeannette
Macdonell, Richard AL
Marriott, Mark
Mason, Deborah F
Parratt, John
Reddel, Stephen W
Shaw, Cameron P
Slee, Mark
Spies, Judith M
Taylor, Bruce V
Carroll, William M
Kilpatrick, Trevor J
King, John
McCombe, Pamela A
Pollard, John D
Willoughby, Ernest
Griffith University Author(s)
Year published
2015
Metadata
Show full item recordAbstract
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history.
- A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease.
While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable.
- The importance of early treatment in minimising long-term disability is increasingly recognised.
Most of the newer, more effective therapies are associated with risks ...
View more >Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. - A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. - The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. - While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.
View less >
View more >Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. - A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. - The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. - While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.
View less >
Journal Title
The Medical Journal of Australia
Volume
203
Issue
3
Copyright Statement
Broadley SA, Barnett MH, Boggild M, et al. A new era in the treatment of multiple sclerosis. Med J Aust 2015; 203 (3): 139-141. © Copyright 2015 The Medical Journal of Australia – reproduced with permission.
Subject
Biomedical and clinical sciences
Clinical sciences not elsewhere classified
Psychology